Der blev ikke registreret statistisk signifikante forskelle i sekundære endepunkter såsom varighed af respons, progressionsfri overlevelse, neurologiske tegn og symptomer, Karnofsky performance status, livskvalitet og samlet overlevelse.
No statistically significant differences were noted in secondary endpoints such as duration of response, progression-free survival, neurological signs and symptoms, Karnofsky performance status, quality of life and overall survival.